Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Upstream Bio, Inc.NASDAQ: UPB
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets rises 1966.6% from a year ago
Other current assets stood at $20.67M at the end of Q1 FY2026, up 1966.6% from a year earlier and up 114.8% from the prior quarter. Over 3 fiscal years it compounded at +245.6% a year.
Context
- Other current assets amounted to 6.5% of total assets at the end of Q1 FY2026, up 6.3 pp from a year earlier.
- Other current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps rising in the next quarterly balance sheet after a +1966.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 9.62M USD
- Year-over-year change
- +1847.4%
- 3-year CAGR
- +245.6%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.62M | +1847.4% |
| FY2024 | 2024-12-31 | 494K | +33.5% |
| FY2023 | 2023-12-31 | 370K | +58.8% |
| FY2022 | 2022-12-31 | 233K | — |
Other Current Assets vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so other current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +1966.6% is the 2nd highest of 9, against a peer median of +31.1%.
- Other current assets amounts to 6.5% of total assets for UPB, versus a peer median of 1.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $81.33M USD | +119.0% | +49.6% | 10.7% | |
| Sep 2026 | $27.82M USD | +51.2% | +51.0% | 2.5% | |
| Mar 2026 | $25.71M USD | -68.6% | +13.0% | 2.5% | |
UPBUpstream Bio, Inc. | Mar 2026 | $20.67M USD | +1966.6% | +245.6% | 6.5% |
| Mar 2026 | $11.86M USD | +118.5% | +86.2% | 1.6% | |
| Mar 2026 | $11.45M USD | +2027.5% | +118.4% | 2.4% | |
| Jun 2026 | $8.41M USD | +11.0% | +22.4% | 0.9% | |
| Mar 2026 | $3.46M USD | -49.5% | +13.4% | 0.6% | |
| Sep 2026 | $0 USD | -100.0% | -13.2% | 0.0% | |
| Sep 2026 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding UPB) | — | +31.1% | +36.0% | 1.6% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.